Genfit S.A. (LON:0QT6)

London flag London · Delayed Price · Currency is GBP · Price in EUR
5.32
-0.04 (-0.65%)
At close: Dec 30, 2025
50.28%
Market Cap231.51M
Revenue (ttm)38.68M
Net Income (ttm)-33.22M
Shares Outn/a
EPS (ttm)-0.70
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,214
Average Volume5,024
Open5.33
Previous Close5.36
Day's Range5.29 - 5.38
52-Week Range2.70 - 5.36
Beta0.87
RSI74.26
Earnings DateDec 23, 2025

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 180
Stock Exchange London Stock Exchange
Ticker Symbol 0QT6
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

There is no news available yet.